试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-09-09
Patient Controlled Remifentanil Analgesia for Normal Labour
编号:NCT04541719登记状态:入组前撤回企业 / 申办者:Mansoura University
药物 / 成分:Patient-controlled remifentanil analgesia、Epidural analgesia
登记的停止原因(原文):no participants enrolled
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-09-07
Nebulized Magnesium Sulfate in Pediatric Asthma
编号:NCT00522444登记状态:入组前撤回企业 / 申办者:Children's Hospital Medical Center, Cincinnati
药物 / 成分:Nebulized Magnesium Sulfate、Nebulized normal saline
登记的停止原因(原文):lack of funding
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-09-07
AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma
编号:NCT04058145登记状态:入组前撤回企业 / 申办者:Massachusetts General Hospital
药物 / 成分:AMD3100、Pembrolizumab
登记的停止原因(原文):Funding Withdrawn
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-09-07
Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers
编号:NCT04106843登记状态:入组前撤回企业 / 申办者:M.D. Anderson Cancer Center
药物 / 成分:Lutetium Lu 177 Dotatate
登记的停止原因(原文):No Participants Registered
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-09-04
An Alternative Dose Interval Study in Participants With Hidradenitis Suppurativa Receiving Brodalumab
编号:NCT04249713登记状态:入组前撤回企业 / 申办者:Rockefeller University
药物 / 成分:Brodalumab
登记的停止原因(原文):Biomarker Samples Not Collected
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-09-04
Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies (HYACINTHE)
编号:NCT04392128登记状态:入组前撤回企业 / 申办者:Institut de cancérologie Strasbourg Europe
药物 / 成分:Hydroxychloroquine Sulfate 200 MG [Plaquenil]、Azithromycin 250 MG Oral Capsule、Placebo oral tablet、Placebo oral capsule
登记的停止原因(原文):competent authority decision
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-09-03
Phase 4 Study of the Efficacy of Losartan Based Therapy in Hypertensives With and Without Diabetes
编号:NCT03978884登记状态:入组前撤回企业 / 申办者:The University of The West Indies
药物 / 成分:Losartan 50Mg Tab、Losartan/Hydrochlorothiazide 50 Mg-12.5 Mg ORAL TABLET、Losartan/Hydrochlorothiazide 100 Mg-25 Mg ORAL TABLET、Amlodipine 5mg
登记的停止原因(原文):Unable to effective arrange trial logistics
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-09-03
Study of CX1106 in Patients With Advanced Head and Neck Squamous Cell Carcinoma
编号:NCT04093115登记状态:入组前撤回企业 / 申办者:Beijing Konruns Pharmaceutical Co., Ltd.
药物 / 成分:CX1106
登记的停止原因(原文):The study was terminated voluntarily by the sponsor due to changes in clinical development strategy.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-09-02
Functional Improvement of Progenitor Cells and Endothelial Function by Vildagliptin in Diabetes Mellitus (FINNjA-DM).
编号:NCT00936234登记状态:入组前撤回企业 / 申办者:Johann Wolfgang Goethe University Hospital
药物 / 成分:Vildagliptin
登记的停止原因(原文):insufficient recruitment
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-09-02
Phosphatidylcholine Supplementation in Infants
编号:NCT01905605登记状态:入组前撤回企业 / 申办者:University of Colorado, Denver
药物 / 成分:phosphatidylcholine supplementation、placebo
登记的停止原因(原文):Funding not secured. IRB approval has been withdrawn as of January 2017.
查看官方原始记录 ↗